Hyo Jeong Hong
Overview
Explore the profile of Hyo Jeong Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hong J, Choi Y, Choi Y, Lee J, Hong H
Vaccines (Basel)
. 2021 Aug;
9(7).
PMID: 34358170
Hepatitis B virus (HBV) is a global health burden that causes acute and chronic hepatitis. To develop an HBV-neutralizing antibody that effectively prevents HBV infection, we previously generated a human...
2.
Nam J, Kim A, Choi S, Kim J, Choi K, Cho S, et al.
Nat Commun
. 2021 Jun;
12(1):3279.
PMID: 34078883
Targeting the molecular pathways underlying the cardiotoxicity associated with thoracic irradiation and doxorubicin (Dox) could reduce the morbidity and mortality associated with these anticancer treatments. Here, we find that vascular...
3.
Quijano-Rubio A, Yeh H, Park J, Lee H, Langan R, Boyken S, et al.
Nature
. 2021 Jan;
591(7850):482-487.
PMID: 33503651
Naturally occurring protein switches have been repurposed for the development of biosensors and reporters for cellular and clinical applications. However, the number of such switches is limited, and reengineering them...
4.
Kim D, Hong J, Choi Y, Han J, Kim S, Jo G, et al.
J Microbiol Biotechnol
. 2020 Sep;
30(11):1760-1768.
PMID: 32876069
, cause of the life-threatening diarrheal disease cholera, can be divided into different serogroups based on the structure of its lipopolysaccharide (LPS), which consists of lipid-A, corepolysaccharide and O-antigen polysaccharide...
5.
Quijano-Rubio A, Yeh H, Park J, Lee H, Langan R, Boyken S, et al.
bioRxiv
. 2020 Aug;
PMID: 32743576
Naturally occurring allosteric protein switches have been repurposed for developing novel biosensors and reporters for cellular and clinical applications , but the number of such switches is limited, and engineering...
6.
Park T, Park J, Lee S, Hong H, Lee S
Biotechnol Bioprocess Eng
. 2020 Mar;
11(2):173.
PMID: 32218672
In this study, a novel strategy was developed for the highly selective immobilization of proteins, using the polyhydroxyalkanoate (PHA) depolymerase substrate binding domain (SBD) as an active binding domain. In...
7.
Song I, Jeong M, Hong H, Shin J, Park Y, Woo S, et al.
Clin Cancer Res
. 2019 Jul;
25(20):6148-6159.
PMID: 31337646
Purpose: Cholangiocarcinoma is a malignancy of bile duct with a poor prognosis. Conventional chemotherapy and radiotherapy are generally ineffective, and surgical resection is the only curative treatment for cholangiocarcinoma. L1-cell...
8.
Kim D, Yoon H, Kim S, Wi J, Chae H, Jo G, et al.
J Microbiol Biotechnol
. 2018 Nov;
28(12):2113-2120.
PMID: 30380821
Cross-reactive material 197 (CRM₁₉₇) is a non-toxic mutant of diphtheria toxin containing a single amino acid substitution of glycine 52 with glutamic acid. CRM₁₉₇ has been used as a carrier...
9.
Jo G, Jeong M, Wi J, Kim D, Kim S, Kim D, et al.
J Microbiol Biotechnol
. 2018 Oct;
28(8):1376-1383.
PMID: 30301315
The hepatitis B virus (HBV) envelope contains small (S), middle (M), and large (L) proteins. PreS1 of the L protein contains a receptor-binding motif crucial for HBV infection. This motif...
10.
Lee D, Lee M, Seo Y, Hong H, An H, Kang J, et al.
Biomaterials
. 2018 Apr;
171:34-45.
PMID: 29679794
Limitation of current anti-Vascular Endothelial Growth Factor (VEGF) cancer therapy is transitory responses, inevitable relapses and its insufficient tumor-targeting. Thus, multifaceted approaches, including the development of bispecific antibodies and combination...